Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Contemporary research has revived interest in psychedelic-assisted therapies, notably psilocybin therapy (PT), following earlier mid-20th century work. The introduction summarises biological and psychological mechanisms proposed to underlie psilocybin's effects: psilocybin acts as a selective partial agonist at cortical 5-HT2A receptors, is thought to modulate the default mode network (DMN), and may promote neuroplasticity. Clinically, small randomised controlled trials (RCTs) and longitudinal studies provide preliminary evidence of safety, tolerability, and efficacy in conditions such as treatment-resistant major depressive disorder (TRD), end-of-life anxiety, and obsessive-compulsive disorder. The extracted text reports specific trial findings, including a 59-participant RCT by Carhart‑Harris et al. that found no significant difference on the primary depression outcome but secondary analyses favouring 25 mg psilocybin, a 233-participant RCT where 37% of the 25 mg group showed a clinically significant response and 26% met remission criteria, and a longitudinal study reporting 58% in remission at 12 months after two doses (20 mg/30 mg). Common acute adverse effects noted include headache, nausea, fatigue and insomnia. Modlin and colleagues argue that psilocybin therapy is not solely a pharmacological intervention but a package intervention combining drug administration with psychological support and contextual factors such as mindset and setting. They identify a gap in current practice and research: although many patients may be medically eligible for PT, little attention has been paid to intrapersonal and interpersonal factors that determine a patient's readiness or capacity to engage with the psychological elements of treatment. The paper therefore sets out to conceptualise "readiness for PT" and to propose a framework—focusing on patient presentation, therapeutic alliance, and patient safety—that could be used to assess readiness and guide personalised preparation to optimise clinical outcomes.

The extracted text does not report a formal empirical study design, systematic review protocol, or original data collection methods. Rather, the paper is a conceptual and synthetic work that draws on prior clinical trials, observational findings, and psychological theory to develop a readiness framework for psilocybin therapy. Across the manuscript the researchers summarise evidence from RCTs and longitudinal studies to motivate the framework, describe procedural elements of PT (preparation, psilocybin dosing, and integration phases), and articulate candidate domains for a future readiness assessment instrument. No systematic search strategy, eligibility criteria for included literature, or quantitative meta-analytic methods are described in the extracted text. The section titled "Development of the Psilocybin Therapy Readiness Scale" presents rationale and conceptual considerations for creating a formalised assessment tool but does not provide psychometric testing, item development methods, or validation results within the provided extraction.

As a conceptual paper, there are no primary empirical results reported. Instead, the authors present a structured synthesis and a set of proposed constructs intended to capture patient readiness for psilocybin therapy. Key elements summarised from prior empirical work include: 25 mg psilocybin dosing produced favourable secondary outcomes in one 59-participant RCT; in a 233-participant RCT with single doses of 1, 10 or 25 mg, 37% of the 25 mg group experienced a clinically significant response and 26% met remission criteria; and a longitudinal cohort reported 58% remission at 12 months after two doses (20 mg/30 mg). Acute side effects commonly reported across studies included headache, nausea, fatigue and insomnia. Building on these findings and theoretical accounts, the paper proposes three core domains of readiness for PT. Patient presentation encompasses modifiable intrapersonal traits and states such as openness (attentiveness to inner feelings, toleration of novel experiences), motivation (behavioural engagement and expectancy of benefit), and affective tolerance (capacity to tolerate challenging emotional states). Therapeutic alliance is framed as agreement on goals and tasks plus interpersonal trust and safety; the authors cite preliminary evidence that alliance quality predicts emotional breakthroughs, mystical-type experiences, and better outcomes. Patient safety includes psychological processes that may elevate risk or undermine benefit, specifically rumination, despair and mental states such as preoccupation and confusion that predict adverse reactions. The authors propose that low levels across these domains may indicate limited readiness and that targeted preparation during the preparation phase could increase readiness and thereby improve engagement and outcomes. Finally, the paper outlines the intended purpose of a Psilocybin Therapy Readiness Scale but does not present empirical validation data for such a tool in the extracted text.

Modlin and colleagues interpret their synthesis to mean that assessing and enhancing patient readiness is a crucial but underdeveloped component of optimising psilocybin therapy. They argue that readiness comprises more than medical eligibility; intrapersonal traits, the quality of the therapeutic relationship, and safety-related psychological states are integral to a patient's capacity to engage with PT and to derive benefit. The discussion positions these factors as potentially predictive of short- and long-term outcomes and as targets for personalised preparatory work within the preparation phase of PT. The authors situate their proposal relative to broader debates in psychedelic research about isolating pharmacological effects from contextual and relational influences. They note that traditional randomised trial designs and double blinding are constrained in psychotherapy research and that expectancy and non‑pharmacological components cannot be fully eliminated. Consequently, the paper calls for viewing extra‑pharmacologic factors—therapeutic alliance, patient characteristics, socio-cultural context and expectations—as essential contextual elements rather than mere confounds. The researchers acknowledge important limitations: the absence of a validated readiness instrument at present, the methodological challenges of testing the incremental impact of readiness assessments in RCTs (including potential mitigation of group differences if preparation is adapted), and the broader need for definitive trials and careful interpretation of placebo/psychedelic comparisons. In terms of implications, the authors suggest that a formalised readiness assessment could enable personalised preparation, reduce the risk of adverse reactions, mitigate potential treatment failures, and improve mechanistic understanding of how PT effects change. They emphasise that rigorous investigation will be required to validate any readiness tool and to determine whether tailoring preparation based on readiness indicators improves clinical and safety outcomes.

The paper concludes that psychedelic-assisted therapies show preliminary promise as safe and effective treatments for several mental health conditions, but that personalised approaches are likely to yield more durable improvements. The authors advocate for assessing "readiness"—a combination of eligibility and capacity—prior to psilocybin dosing, focusing on patient presentation, therapeutic alliance, and safety. They contend that identifying and targeting deficits across these domains through tailored preparation could optimise psychological support, enhance the therapeutic effect of psilocybin, and reduce the likelihood of adverse outcomes. The extracted text reiterates that a formalised readiness assessment has potential value but requires careful validation and thoughtful integration into clinical research and practice.